CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-02 | Vasista Vittal Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +76,313 | 76,313 | ||
| 2024-01-02 | Mills Kenneth T. President and CEO | Shares withheld for taxes | −11,357 | $17.95 | $204K | 343,932 |
| 2024-01-02 | Mills Kenneth T. President and CEO | Grant or award | +64,103 | 408,035 | ||
| 2024-01-02 | Mills Kenneth T. President and CEO | Grant or award · Stock Options (Right to buy) | +305,250 | 305,250 | ||
| 2024-01-02 | Christmas Patrick J. Chief Legal Officer | Shares withheld for taxes | −7,893 | $17.95 | $142K | 81,144 |
| 2024-01-02 | Christmas Patrick J. Chief Legal Officer | Grant or award | +34,615 | 115,759 | ||
| 2024-01-02 | Christmas Patrick J. Chief Legal Officer | Grant or award · Stock Options (Right to buy) | +54,945 | 54,945 | ||
| 2023-12-19 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +43,500 | $3.76 | $164K | 398,789 |
| 2023-12-19 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +1,500 | $0.85 | $1K | 400,289 |
| 2023-12-19 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −45,000 | $19.69 | $886K | 355,289 |
| 2023-12-19 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −43,500 | 186,354 | ||
| 2023-12-19 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −1,500 | 36,316 | ||
| 2023-06-30 | Danos Olivier Chief Scientific Officer | Grant or award | +1,123 | $16.99 | $19K | 94,801 |
| 2023-06-02 | Fox Allan M. Director | Grant or award | +3,486 | 6,496 | ||
| 2023-06-02 | Fox Allan M. Director | Grant or award · Stock Options (Right to Buy) | +17,892 | 17,892 | ||
| 2022-06-30 | Danos Olivier Chief Scientific Officer | Grant or award | +728 | $21.00 | $15K | 93,678 |
Page 11 of 11 · 216 trades